Follow
Urania Dafni
Urania Dafni
Professor of Biostatistics, National and Kapodistrian University of Athens, Greece
Verified email at nurs.uoa.gr
Title
Cited by
Cited by
Year
A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical …
NI Cherny, R Sullivan, U Dafni, JM Kerst, A Sobrero, C Zielinski, ...
Annals of Oncology 26 (8), 1547-1573, 2015
8822015
Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial
L Gianni, U Dafni, RD Gelber, E Azambuja, S Muehlbauer, A Goldhirsch, ...
The lancet oncology 12 (3), 236-244, 2011
8072011
Prognostic significance of autoimmunity during treatment of melanoma with interferon
H Gogas, J Ioannovich, U Dafni, C Stavropoulou-Giokas, K Frangia, ...
New England Journal of Medicine 354 (7), 709-718, 2006
7632006
Malignant lymphoma in primary Sjögren's syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjögren's Syndrome
M Voulgarelis, UG Dafni, DA Isenberg, HM Moutsopoulos
Arthritis & Rheumatism: Official Journal of the American College of …, 1999
6411999
Clinical evolution, and morbidity and mortalityof primary Sjögren's syndrome
FN Skopouli, U Dafni, JPA Ioannidis, HM Moutsopoulos
Seminars in arthritis and rheumatism 29 (5), 296-304, 2000
6372000
ESMO-magnitude of clinical benefit scale version 1.1
NI Cherny, U Dafni, J Bogaerts, NJ Latino, G Pentheroudakis, ...
Annals of oncology 28 (10), 2340-2366, 2017
5772017
Landmark analysis at the 25-year landmark point
U Dafni
Circulation: Cardiovascular Quality and Outcomes 4 (3), 363-371, 2011
4732011
Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer
JL Tanyi, S Bobisse, E Ophir, S Tuyaerts, A Roberti, R Genolet, ...
Science translational medicine 10 (436), eaao5931, 2018
3802018
Zidovudine treatment of the AIDS dementia complex: results of a placebo‐controlled trial
JJ Sidtis, C Gatsonis, RW Price, EJ Singer, AC Collier, DD Richman, ...
Annals of neurology 33 (4), 343-349, 1993
3651993
Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection
CD Hall, U Dafni, D Simpson, D Clifford, PE Wetherill, B Cohen, ...
New England Journal of Medicine 338 (19), 1345-1351, 1998
3601998
Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial
M Procter, TM Suter, E De Azambuja, U Dafni, V Van Dooren, ...
Journal of Clinical Oncology 28 (21), 3422-3428, 2010
3292010
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised …
M O’Brien, L Paz-Ares, S Marreaud, U Dafni, K Oselin, L Havel, E Esteban, ...
The Lancet Oncology 23 (10), 1274-1286, 2022
3122022
Blood leptin and adiponectin as possible mediators of the relation between fat mass and BMD in perimenopausal women
MD Kontogianni, UG Dafni, JG Routsias, FN Skopouli
Journal of Bone and Mineral Research 19 (4), 546-551, 2004
2762004
Prevalence of Sjögren’s syndrome in a closed rural community
UG Dafni, AG Tzioufas, P Staikos, FN Skopouli, HM Moutsopoulos
Annals of the rheumatic diseases 56 (9), 521-525, 1997
2431997
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial
R Rosell, U Dafni, E Felip, A Curioni-Fontecedro, O Gautschi, S Peters, ...
The Lancet Respiratory Medicine 5 (5), 435-444, 2017
2142017
Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial
M Dowsett, M Procter, W McCaskill-Stevens, E de Azambuja, U Dafni, ...
Journal of clinical oncology 27 (18), 2962, 2009
2132009
Low-dose radiotherapy reverses tumor immune desertification and resistance to immunotherapy
FG Herrera, C Ronet, M Ochoa de Olza, D Barras, I Crespo, M Andreatta, ...
Cancer discovery 12 (1), 108-133, 2022
2082022
Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project
FH Blackhall, S Peters, L Bubendorf, U Dafni, KM Kerr, H Hager, ...
Journal of clinical oncology 32 (25), 2780-2787, 2014
2032014
Evaluating surrogate markers of clinical outcome when measured with error
UG Dafni, AA Tsiatis
Biometrics, 1445-1462, 1998
1961998
Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis
U Dafni, O Michielin, SM Lluesma, Z Tsourti, V Polydoropoulou, D Karlis, ...
Annals of Oncology 30 (12), 1902-1913, 2019
1942019
The system can't perform the operation now. Try again later.
Articles 1–20